Oral News and Research

RSS

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Elan Corporation, plc today announced that it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.

30 Aug 2012

Jobless working-age people with diabetes less likely to adhere to their medications

If you're diabetic or prone to diabetes, having a steady job appears to be good for your health, and not just because of the insurance coverage.

30 Aug 2012

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.

30 Aug 2012

Neuromuscular block may not hamper facemask airway success

It may not be necessary to wait to establish good facemask ventilation before administering neuromuscular block, a study suggests.

29 Aug 2012

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised "Guidelines on the Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation (STEMI)" guidelines.

29 Aug 2012

Omitting aspirin leads to less bleedings but does not increase risk of stent thrombosis, MI

Lifelong anticoagulation is necessary for the prevention of stroke in patients with rhythm disturbances and with mechanical valves. Patients who have a coronary stent implanted also need the antiplatelet drugs aspirin and clopidogrel to prevent the rare but lethal complication of stent thrombosis.

29 Aug 2012

Aeterna Zentaris commences enrollment in AEZS-130 Phase 2A trial for cancer cachexia

Aeterna Zentaris Inc. today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia.

28 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Allegro Diagnostics announces results from BronchoGen genomic test trial on lung cancer

Allegro Diagnostics today announced that results from its AEGIS (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trials, to determine the accuracy of the BronchoGen genomic test, have been accepted for an oral presentation during the late-breaking abstract session at CHEST 2012 on Tuesday, October 23, 2012 at 4:30 p.m. The abstract will also be published in a supplement of the October 2012 issue of CHEST.

28 Aug 2012

Novartis receives EC approval for Jakavi to treat myelofibrosis

Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

28 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Perrigo Company and Tris Pharma, Inc. today announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym extended–release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

27 Aug 2012

Oral News and Research

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Jobless working-age people with diabetes less likely to adhere to their medications

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

Neuromuscular block may not hamper facemask airway success

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

Omitting aspirin leads to less bleedings but does not increase risk of stent thrombosis, MI

Aeterna Zentaris commences enrollment in AEZS-130 Phase 2A trial for cancer cachexia

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Allegro Diagnostics announces results from BronchoGen genomic test trial on lung cancer

Novartis receives EC approval for Jakavi to treat myelofibrosis

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

Regulating microbes could help prevent diseases associated with obesity

Female sex associated with increased risk of stroke for AF patients aged ≥75 years

Children with obesity face increased risk for gallstones

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Vandetanib shows efficacy in thyroid cancer

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News